SYMBERIX, INC.

Durham, NC · Biotech · Private

Small-molecule GUS enzyme inhibitors to prevent drug-induced gastrointestinal adverse events by targeting microbiome-mediated drug metabolism

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Durham, NC
Total capital: $7.9M

Federal grants: $7.7M; 13 awards · 2015–2022; Rank in peer group#80 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $269K; 1 award · Health and Human S; Rank in Biotech#277 of 4373
Granted patents: 1; 5 pending · first 2024; Rank in peer group#186 of 514

Capital timeline

Latest events

Jun 2022Federal grantHealth and Human S · Phase I · Small molecule drugs targeting gut dysbiosis to manage inflammatory bowel disease$305K
Jun 2021Federal grantHealth and Human S · Phase II · Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs$847K
May 2021Federal grantHealth and Human S · Phase II · Developing novel inhibitors of the gut microbiome to modulate drug metabolism$788K
Jul 2020Federal grantHealth and Human S · Phase II · Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs$884K
Jun 2020Federal grantHealth and Human S · Phase II · Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$999K
May 2020Federal grantHealth and Human S · Phase II · Developing novel inhibitors of the gut microbiome to modulate drug metabolism$1.4M
Sep 2019Federal grantHealth and Human S · Phase II · Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$988K

Show 7 earlier federal awards

May 2019Federal grantHealth and Human S · Phase I · Modulation of gut dysbiosis with Enterobacteriaceae-targeted antiproliferative agents to treat inflammatory bowel disease$231K
Apr 2019Federal grantHealth and Human S · Phase II · Developing novel inhibitors of the gut microbiome to modulate drug metabolism$225K
Aug 2018Federal grantHealth and Human S · Phase II · Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$300K
Apr 2018Federal grantHealth and Human S · Phase I · Therapeutic Adjunct to Improve Immunosuppression Outcomes Following Organ Transplantation$238K
Mar 2018Federal grantHealth and Human S · Phase I · The Benchtop Symbiome: developing an integrated mammalian-microbial assay platform to accelerate microbiome-targeted drug discovery$221K
Sep 2016Federal contractHealth and Human S · Igf::ot::igf SBIR Phase I, Topic 351: Improving Targeted Cancer Therapies By Modulating The Intestinal Microbiome$269K
Sep 2015Federal grantHealth and Human S · Phase I · Microbiome Targeted Drugs to Improve NSAID Outcomes$216K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#80 · top 16%
Granted patents#186 · top 36%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 6

Dec 19, 2024PendingCOMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEAUSPTOApplication 18659997
Jun 25, 2024GrantedCOMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEAUSPTOUS 12,017,994
Apr 28, 2022PendingCompounds, Compositions, And Methods For Selectively Inhibiting Beta-glucuronidases And Alleviating Side Effects Associated With Drug Treatment Induced DiarrheaUSPTOApplication 17436246

Show all 6 patent records

COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEADec 19, 2024 · Application 18659997Pending
COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEAJun 25, 2024 · US 12,017,994Granted
Compounds, Compositions, And Methods For Selectively Inhibiting Beta-glucuronidases And Alleviating Side Effects Associated With Drug Treatment Induced DiarrheaApr 28, 2022 · Application 17436246Pending
Compounds, Compositions, And Methods For Selectively Inhibiting B-glucuronidases And Alleviating Side Effects Associated With Drug Treatment Induced DiarrheaApplication PCTUS2020021416Pending
Compounds, Compositions, And Methods For Selectively Inhibiting Beta-glucuronidases And Alleviating Side Effects Associated With Drug Treatment Induced DiarrheaApplication 62815096Pending
Compounds, Compositions, And Methods For Selectively Inhibiting B-glucuronidases And Alleviating Side Effects Associated With Drug Treatment Induced DiarrheaApplication PCTUS2018049891Pending

CASTERBRIDGE PHARMACEUTICALS INCSimilar federal contract value in Biotech · $297K in contracts
VASCULAR VISION PHARMACEUTICAL COSimilar federal contract value in Biotech · $289K in contracts
Organovo, Inc.Similar federal contract value in Biotech · $284K in contracts
ZymergenSimilar federal contract value in Biotech · $267K in contracts
LEXICON PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $263K in contracts
AllCells, LLCSimilar federal contract value in Biotech · $261K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.